Katherine Smith

Hematology | Oncology
200 1st St SW
Rochester, MN 55905

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications

Amivantamab Induces Immune-Mediated Cytotoxicity in Mesothelioma Through EGFR and MET Engagement.

Amivantamab Induces Immune-Mediated Cytotoxicity in Mesothelioma Through EGFR and MET Engagement.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: March 11, 2026

Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in RET-Altered Solid Tumors: Analysis of the RETgistry Global Consortium.

Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in RET-Altered Solid Tumors: Analysis of the RETgistry Global Consortium.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: November 17, 2025

Evaluating therapeutic plasma exchange and protease inhibitors as mechanisms to reduce soluble mesothelin.

Evaluating therapeutic plasma exchange and protease inhibitors as mechanisms to reduce soluble mesothelin.

Journal: Scientific reports
Published: November 23, 2024

Personalized Medicine in Histiocytic Disorders: Novel Targets in Patients Without MAPK Alterations.

Personalized Medicine in Histiocytic Disorders: Novel Targets in Patients Without MAPK Alterations.

Journal: JCO precision oncology
Published: November 22, 2024

Randomized trial of anetumab ravtansine and pembrolizumab compared to pembrolizumab for mesothelioma.

Randomized trial of anetumab ravtansine and pembrolizumab compared to pembrolizumab for mesothelioma.

Journal: Lung cancer (Amsterdam, Netherlands)
Published: June 12, 2024

The Timing, Trajectory, and Incidence of Immune-Related Adverse Events in NSCLC Treated With Atezolizumab.

The Timing, Trajectory, and Incidence of Immune-Related Adverse Events in NSCLC Treated With Atezolizumab.

Journal: JTO clinical and research reports
Published: September 15, 2023

A phase I oncolytic virus trial with vesicular stomatitis virus expressing human interferon beta and tyrosinase related protein 1 administered intratumorally and intravenously in uveal melanoma: safety, efficacy, and T cell responses.

A phase I oncolytic virus trial with vesicular stomatitis virus expressing human interferon beta and tyrosinase related protein 1 administered intratumorally and intravenously in uveal melanoma: safety, efficacy, and T cell responses.

Journal: Frontiers in immunology
Published: August 17, 2023

Persistent Tumor Mutational Burden (pTMB) May Predict Response to Immune Checkpoint Inhibitors.

Persistent Tumor Mutational Burden (pTMB) May Predict Response to Immune Checkpoint Inhibitors.

Journal: Clinical chemistry
Published: March 17, 2023

Validating chemoimmunotherapy in small-cell lung cancer.

Validating chemoimmunotherapy in small-cell lung cancer.

Journal: The Lancet. Oncology
Published: April 29, 2022

MAP kinases differentially bind and phosphorylate NOS3 via two unique NOS3 sites.

MAP kinases differentially bind and phosphorylate NOS3 via two unique NOS3 sites.

Journal: FEBS open bio
Published: October 15, 2021

Clinical Outcomes and Racial Disparities in Metastatic Hormone-Sensitive Prostate Cancer in the Era of Novel Treatment Options.

Clinical Outcomes and Racial Disparities in Metastatic Hormone-Sensitive Prostate Cancer in the Era of Novel Treatment Options.

Journal: The oncologist
Published: March 31, 2021

Knowledge of and Attitudes Toward Perinatal Home Visiting in Women with High-Risk Pregnancies.

Knowledge of and Attitudes Toward Perinatal Home Visiting in Women with High-Risk Pregnancies.

Journal: Journal of midwifery & women's health
Published: February 11, 2020
Showing 1-12 of 13

Last Updated: 09/26/2026